Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| NBTXR3 +/- Cetuximab | Head and neck cancer | Phase 3 | Jun 30, 2027 | — |
| RT + NBTXR3 + Chemotherapy | Esophageal cancer | Phase 1/2 | Dec 31, 2026 | Mgmt interest |
| RT + NBTXR3 | Cancer, Pancreatic cancer | Phase 1b | Dec 31, 2026 | Mgmt interest |
Upcoming milestones
Company profile
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Esophageal cancer
Data readoutCancer, Pancreatic cancer
Data readout